Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by jopatcloon Jan 23, 2025 6:41am
10 Views
Post# 36416520

RE:RE:Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀

RE:RE:Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀Interesting on Linkedin see Us2.ai & the first hospital in Vietnam to deploy AI for echocardiography!
Us2.ai on Linkedin https://suckhoedoisong.vn/benh-vien-dau-tien-o-viet-nam-ung-dung-ai-trong-sieu-am-tim-169250121200234929.htm
Us2.ai is honored to partner with AstraZeneca to bring our software to the University of Medicine and Pharmacy, Ho Chi Minh City, making them the first hospital in Vietnam to deploy AI for echocardiography!

We’re thrilled to see how our solution can make a meaningful impact at their institution and help advance cardiac care in the region!

AI AIEcho Echocardiography Innovation PatientsFirst Cardiology
Congratulations to University of Medicine and Pharmacy, Ho Chi Minh City on becoming the first hospital in Vietnam to deploy AI for echocardiography!

Khoi Le Minh, MD, FACC - Head of the Cardiovascular Imaging Unit, University of Medicine and Pharmacy Hospital, Ho Chi Minh City said that "AI can significantly shorten the diagnosis time from 35-40 minutes to about 10 minutes. This helps reduce the workload for medical staff, limit errors as well as save treatment costs."

This achievement marks a transformative milestone in cardiac care for Vietnam. By integrating Us2.ai's cutting-edge AI technology, the hospital is setting a new standard for faster and more accurate echocardiogram analysis, allowing clinicians to focus on what truly matters: delivering better outcomes for patients.

We are honored to partner alongside AstraZeneca and this prestigious institution to advance healthcare innovation. Together, we are shaping the future of cardiology.

Read More: https://lnkd.in/gYVVX5Re

Innovation AIinHealthcare Echocardiography AI Cardiology Ultrasound

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities